Steering Company Into Financial Strength Is Top Priority
For Experienced Financial Officer
CARLSBAD, Calif., June 20 /PRNewswire-FirstCall/ --
The Immune Response Corporation (Nasdaq: IMNR) today announced the appointment
of Michael L. Jeub as vice president of finance and chief financial officer,
positions under which he will oversee the company's ongoing financial
operations and capital needs.
"Michael brings over 25 years in financial management experience to the
company and we are fortunate to have someone of his experience and skill
working with our investors and stockholders," said Dr. Dennis Carlo, president
and chief executive officer of The Immune Response Corporation. "As we
continue taking steps in an effort to ensure the company's success and the
commercialization of our REMUNE(R) product, Michael is a key part of our
management team and strengthens us for the job ahead."
"This is a wonderful opportunity to work with an experienced management
and scientific team on products that may potentially have a significant impact
on a population facing the terrible toll HIV and AIDS inflicts," Jeub said.
"I look forward to bringing my skills in financing and capital formation to
bear on Immune Response and hope to see this company through to its eventual
success."
Mr. Jeub has extensive experience in healthcare and related industries.
Mr. Jeub was chief financial officer, most recently, for Jenny Craig,
International. Prior to that Mr. Jeub served as chief financial officer for
National Health Laboratories, Medical Imaging Centers of America and
International Clinical Laboratories.
Jeub earned his bachelor degree in accounting from California State
Polytechnic University in Pomona, beginning his career at the Los Angeles
office of the accounting firm Ernst & Young. Mr. Jeub currently is also a
partner with Tatum CFO Partners, LLP.
Co-founded by medical pioneer Dr. Jonas Salk and based in Carlsbad,
Calif., The Immune Response Corporation is a biopharmaceutical company
developing immune-based therapies designed to treat HIV, autoimmune diseases
and cancer. The Company also develops and holds patents on several
technologies that can be applied to genes in order to increase gene expression
or effectiveness, making it useful in a wide range of therapeutic applications
for a variety of disorders. Company information is also available at
http://www.imnr.com .
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, that Transamerica might in the future declare
the Company to be in default of its debt arrangements, accelerate the
Company's debt and seize its assets, whether data generated from previous
trials can be replicated in future clinical trials, whether clinical trials
will be successfully concluded, whether REMUNE(R) will be approved for
marketing or be successfully commercialized and whether the Company will be
able to obtain additional financing. Those factors, among others, are
discussed more thoroughly in The Immune Response Corporation's SEC filings,
including but not limited to its report on Form 10-K for the year ended
December 31, 2001 and report on Form 10-Q for the quarter ended March 31,
2002. The Company undertakes no obligation to publicly release the result of
any revisions to these forward-looking statements, which may be made to
reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
Media, James Lee of The Lee Strategy Group,
+1-310-229-5771, Fax, +1-310-229-5772, jlee@leestrategy.com, for
The Immune Response Corporation; or Investors, Kathy Lane of The
Immune Response Corporation, +1-760-771-2236, Fax,
+1-760-771-2140, info@imnr.com
|
